Psoriasis: Immunopathology and immunomodulation

Dermatologic Clinics

Volumn 19, Issue 4, 2001, Pages 649-657

  Gottlieb, Alice B ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CD 80 ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFALIZUMAB; ETANERCEPT; ETRETIN; GALIXIMAB; HYBRID PROTEIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 8 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; PRIMATIZED; RETINOL DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANTIGEN PRESENTING CELL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PSORIASIS; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0034763861     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70306-5     Document Type: Article

References (66)

1. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
2. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 Therapy: A new therapeutic approach
3. PUVA therapy decreases HLA-DR + CDia + Langerhans cells and epidermal cell antigen-presenting capacity in human skin, but flow cytometrically-sorted residual HLA-DR + CDia + Langerhans cells exhibit normal alloantigen-presenting function
4. Intraepidermal lymphocytes in psoriatic lesions are activated GMP17(TIA-1) + CD8 + CD3 + CTLs as determined by phenotypic analysis
5. Intracellular TNF-alpha, IFN-gamma, and IL-2 identify TC1 and TH1 effector populations in psoriasis vulgaris plaque lymphocytes: Single-cell analysis by flow cytometry
6. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients
7. The immunology of psoriasis
8. Epidermal T lymphocytes and HLA-DR expression in psoriasis
9. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: The effects of PUVA treatment
10. Nuclear factor-kappaB-A pivotal transcription factor in chronic inflammatory diseases
11. Help for cytotoxic-T-cell responses is mediated by CD 40 signalling
12. Use of cyclosporin in psoriasis
13. Necrotizing vasculitis and exacerbation of psoriasis after granulocyte colony-stimulating factor for small cell lung carcinoma
14. PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis
15. Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris: Evidence that epidermal immunocytes are direct therapeutic targets
16. 1a,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice
17. Differential expression of ICAM-1, E-selectin and VCAM-1 by endothelial cells in psoriasis and contact dermatitis
18. Increased expression of adhesion receptors in both lesional and nonlesional psoriatic skin
19. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial
20. Worsening psoriasis after treatment with G-CSF in a patient with smallcell lung cancer
21. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations
22. The effect of tacalcitol (1,24(OH)2D3 on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: A placebo-controlled, double-blind study
23. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice
24. Results of a single dose, dose-escalting trial of anti-B7.1 monoclonal antibody (DEC-114) in patients with psoriasis
25. Effects of administration of a single dose of a humanized monoclonal antibody to CD 11a on the immunobiology and clinical activity of psoriasis
26. Use of the interleukin-2 fusion protein, DAB389IL- 2, for the treatment of psoriasis
27. Studies of the effect of cyclosporine in psoriasis in vivo: Combined effects on activated T lymphocytes and epidermal regenerative maturation
28. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of an anti-CD11a antibody
29. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques
30. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
31. Etretinate promotes keratinocyte terminal differentiation and reduces T-cell infiltration in psoriatic epidermis
32. In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of Cyclosporin A
33. Lymphokine gene expression in vivo is inhibited by cyclosporin A
34. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells: Kinetics, mitogen requirements, and effects of cyclosporin A
35. Stimulation of lymphokine release from T lymphoblasts: Requirement for mRNA synthesis and inhibition by cyclosporin A
36. Evidence that cyclosporine inhibits cell-mediated immunity primarily at the level of the T lymphocyte rather than the accessory cells
37. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promotor
38. Interleukin 2 and granulocyte-macrophage colony-stimulating factor induce a perivascular lymphocytic infiltrate in a skin explant model
39. Differential effects of cyclosporine A on langerhans cells and regulatory T-cell populations in severe psoriasis: An immunohistochemical and flow cytometric analysis
40. Methotrexate therapy of psoriasis: Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate
41. Psoriasis with articular involvement induced by interferon alfa
42. Role of the CD28 receptor in T-cell activation
43. Flare of psoriasis and psoriatic arthritis following treatment with granulocyte colony-stimulating factor
44. Cyclosporine in psoriasis treatment: Inhibition of keratinocyte cellcycle progression in G1 independent of effects on transforming growth factor-alpha/epidermal growth factor receptor pathways
45. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization
46. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis
47. Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infiltration in posoriatic plaques by topical calcitriol
48. Immunopharmacologic effects of Amevive (LFA3TIP) in chronic plaque psoriasis: Selectivity for peripheral memory-effector (CD45RO +) over Naive (CD45RA +) T cells
49. Pharmacodynamic effects of LFA3TIP (Amevive) in patients with chronic plaque psoriasis (CPP): Selective modulation of CD45RO+ lymphocytes
50. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
51. Dermal dendritic cells are important members of the skin immune system
52. Treatment with antitumor necrosis factor-alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
53. 312-Nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions
54. ELAM- 1 is an adhesion melecule for skin homing T cells
55. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
56. Regulation of lymphokine production and human T lymphocyte activation by 1,25-didydroxyvitamin D 3
57. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: A cell cycle analysis
58. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD 40L interactions
59. Adhesions receptors of the immune system
60. IL-11 is an immune-modulatory cytokine which downregulates IL-12, Type 1 cytokines, and multiple inflammationassociated genes in patients with psoriasis
61. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy
62. Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation
63. E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic plaques
64. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis
65. Successful ultraviolet B treatment of psoriasis is accompanied by reversal of keratinocyte pathology and by selective depletion of intraepidermal T-cells
66. Dermal injection of immunocytes induces psoriasis